A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 6,864 shares of BMRN stock, worth $435,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,864
Previous 6,528 5.15%
Holding current value
$435,314
Previous $537,000 10.24%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$69.02 - $93.84 $23,190 - $31,530
336 Added 5.15%
6,864 $482,000
Q2 2024

Jul 19, 2024

SELL
$74.43 - $92.22 $65,870 - $81,614
-885 Reduced 11.94%
6,528 $537,000
Q1 2024

Apr 22, 2024

BUY
$83.81 - $99.0 $6,034 - $7,128
72 Added 0.98%
7,413 $647,000
Q4 2023

Jan 16, 2024

SELL
$76.22 - $98.51 $1.11 Million - $1.43 Million
-14,508 Reduced 66.4%
7,341 $707,000
Q3 2023

Oct 24, 2023

BUY
$85.07 - $94.48 $189,876 - $210,879
2,232 Added 11.38%
21,849 $1.93 Million
Q2 2023

Jul 25, 2023

SELL
$86.68 - $100.3 $285,003 - $329,786
-3,288 Reduced 14.35%
19,617 $1.7 Million
Q1 2023

Apr 14, 2023

BUY
$87.74 - $117.27 $756,318 - $1.01 Million
8,620 Added 60.34%
22,905 $2.23 Million
Q4 2022

Feb 08, 2023

SELL
$80.93 - $108.63 $77,288 - $103,741
-955 Reduced 6.27%
14,285 $1.48 Million
Q3 2022

Oct 25, 2022

BUY
$82.16 - $96.94 $70,904 - $83,659
863 Added 6.0%
15,240 $1.29 Million
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $175,912 - $213,737
-2,461 Reduced 14.62%
14,377 $1.19 Million
Q1 2022

May 11, 2022

BUY
$74.28 - $92.69 $866,996 - $1.08 Million
11,672 Added 225.94%
16,838 $1.3 Million
Q4 2021

Feb 08, 2022

SELL
$71.72 - $91.47 $363,476 - $463,569
-5,068 Reduced 49.52%
5,166 $456,000
Q3 2021

Nov 02, 2021

SELL
$74.77 - $85.47 $173,765 - $198,632
-2,324 Reduced 18.51%
10,234 $791,000
Q2 2021

Aug 11, 2021

BUY
$75.51 - $84.79 $359,805 - $404,024
4,765 Added 61.14%
12,558 $1.05 Million
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $181,220 - $219,923
2,425 Added 45.18%
7,793 $588,000
Q4 2020

Feb 12, 2021

BUY
$72.61 - $90.2 $81,323 - $101,024
1,120 Added 26.37%
5,368 $471,000
Q3 2020

Nov 04, 2020

SELL
$71.87 - $131.03 $2,156 - $3,930
-30 Reduced 0.7%
4,248 $323,000
Q2 2020

Jul 17, 2020

BUY
$79.55 - $124.22 $340,314 - $531,413
4,278 New
4,278 $528,000
Q1 2020

Apr 21, 2020

SELL
$71.37 - $96.85 $340,078 - $461,490
-4,765 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$64.27 - $86.37 $306,246 - $411,553
4,765 New
4,765 $403,000
Q3 2019

Nov 07, 2019

SELL
$67.4 - $85.11 $161,760 - $204,264
-2,400 Closed
0 $0
Q2 2019

Aug 06, 2019

SELL
$80.35 - $93.9 $74,323 - $86,857
-925 Reduced 27.82%
2,400 $206,000
Q1 2019

May 06, 2019

BUY
$84.2 - $98.62 $49,004 - $57,396
582 Added 21.22%
3,325 $295,000
Q4 2018

Feb 11, 2019

SELL
$80.14 - $106.07 $58,101 - $76,900
-725 Reduced 20.91%
2,743 $234,000
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $79,080 - $89,016
842 Added 32.06%
3,468 $336,000
Q2 2018

Jul 30, 2018

SELL
$76.01 - $99.03 $37,776 - $49,217
-497 Reduced 15.91%
2,626 $247,000
Q1 2018

Apr 16, 2018

BUY
$77.67 - $92.63 $47,068 - $56,133
606 Added 24.08%
3,123 $253,000
Q4 2017

Feb 09, 2018

BUY
$80.76 - $95.13 $203,272 - $239,442
2,517
2,517 $224,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.